MedTrace Logo

Effects of Lactobacillus Reuteri Plus Vitamin D3 in Children With Atopic Dermatitis

NCT02945683 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2023-03-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate in a randomized, double-blinded, controlled trial, whether a new food supplement containing Lactobacillus reuteri DSM 17938 and vitamin D3 (Reuterin® D3) may improve the SCORAD in pediatric patients with mild to moderate atopic dermatitis

Conditions

Interventions

DIETARY_SUPPLEMENT

Reuterin D3

Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide

DIETARY_SUPPLEMENT

Placebo

sunflower oil, medium chain triglycerides, silicon dioxide

Sponsors & Collaborators

  • Noos S.r.l.

    lead INDUSTRY

Principal Investigators

  • Attilio Boner, Professor · Policlinico G.B. Rossi, Head of the Pediatric Department

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
4 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2017-02-28
Completion
2018-02-28

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02945683 on ClinicalTrials.gov